Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitafloxacin in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT05400369Phase 4Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sitafloxacin in chronic obstructive pulmonary disease (COPD), sponsored by Daiichi Sankyo Co., Ltd.. Started Aug 2022; status: completed.
02
Drugs
sitafloxacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05400369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400369.